Mankind Pharma: Decent outlook along with M&A catalyst
已更新
The stock dropped 4% after BSV acquisition announcement on Friday slid a little more to support levels of 2045 and bounced back to close at 2063.
The Co. will be announcing earnings which if goes well, the company can break through 2,200 resistance and move upwards.
The company also has regulatory approvals pending from:
-Competition Commission of India
-Turkish Competition Authority
-Federal Ministry of Economic Affairs and Climate Action, Germany
If everything goes as planned these approvals could act as a further catalyst to the stock.
Analyst price the stock at:
Kotak: 2370Rs
Antique: 2438Rs
MOFSL: 2650Rs
Dolat: 2554Rs
avg upside of 21% from current price of 2063Rs
The Co. will be announcing earnings which if goes well, the company can break through 2,200 resistance and move upwards.
The company also has regulatory approvals pending from:
-Competition Commission of India
-Turkish Competition Authority
-Federal Ministry of Economic Affairs and Climate Action, Germany
If everything goes as planned these approvals could act as a further catalyst to the stock.
Analyst price the stock at:
Kotak: 2370Rs
Antique: 2438Rs
MOFSL: 2650Rs
Dolat: 2554Rs
avg upside of 21% from current price of 2063Rs
評論
Would add more at this price (2000 INR)免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。